rct
    2016
    High Quality

    Efficacy and safety of betahistine treatment in patients with Meniere's disease: primary results of a long term, multicentre, double blind, randomised, placebo controlled, dose defining trial (BEMED trial)

    Unknown authors

    Published in BMJ

    Key Findings

    Betahistine at either dose did not reduce vertigo attack frequency compared with placebo over nine months.

    Conclusions

    Well-designed negative trial for the most commonly prescribed vertigo drug.

    Related Health Concerns

    Vertigo Disorder

    Study Details

    Year:2016
    Quality Score:9/10

    Access Study

    View on DOIView on PubMedOriginal Source

    This information is for educational purposes only. Always consult a healthcare professional before starting any supplement regimen.